Recent News

• 11.05.2026 - MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
• 10.29.2026 - MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
• 10.14.2026 - MannKind to Participate in the Chardan Healthcare Conference
• 10.10.2026 - MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
• 09.09.2026 - MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
• 09.02.2026 - MannKind to Present at Upcoming Investor Conferences
• 08.05.2026 - MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.29.2026 - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
• 07.28.2026 - MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
• 07.24.2026 - MannKind Announces $50 Million Private Placement

Recent Filings

• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 09.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.25.2026 - 144 Report of proposed sale of securities
• 09.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 144 Report of proposed sale of securities
• 08.21.2026 - 8-K Current report
• 08.21.2026 - 424B7 Prospectus [Rule 424(b)(7)]
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors